In a dual-center, two-cohort study, researchers combined single-cell RNA-sequencing and single-cell proteomics of whole blood and peripheral blood mononuclear cells to determine changes in immune cell composition and activation in mild vs. severe COVID-19 over time.
6445212 UMPQ7JI6 items 1 apa default asc 1
Schulte-Schrepping, J., Reusch, N., Paclik, D., Baßler, K., Schlickeiser, S., Zhang, B., Krämer, B., Krammer, T., Brumhard, S., Bonaguro, L., Domenico, E. D., Wendisch, D., Grasshoff, M., Kapellos, T. S., Beckstette, M., Pecht, T., Saglam, A., Dietrich, O., Mei, H. E., … Sander, L. E. (2020). Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell, 0(0). https://doi.org/10.1016/j.cell.2020.08.001 Cite
BioAegis Therapeutics, Inc. announced that it enrolled its first patient in its Phase II study of hospitalized patients with severe COVID-19 pneumonia.
[BioAegis Therapeutics, Inc. (GlobeNewswire, Inc.)]
IMV, Inc. announced that Canadian government agencies will contribute up to CA$4.75 million to advance Phase I clinical development of its vaccine candidate, DPX-COVID-19, for the prevention of COVID-19 infection caused by the novel coronavirus SARS-COV-2.
By employing single-cell analysis of the immune cell composition of two severe-stage COVID-19 patients prior to and following tocilizumab-induced remission, investigators identified a monocyte subpopulation that contributes to the inflammatory cytokine storms.
6445212 BKTLULRK items 1 apa default asc 1
Guo, C., Li, B., Ma, H., Wang, X., Cai, P., Yu, Q., Zhu, L., Jin, L., Jiang, C., Fang, J., Liu, Q., Zong, D., Zhang, W., Lu, Y., Li, K., Gao, X., Fu, B., Liu, L., Ma, X., … Qu, K. (2020). Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. Nature Communications, 11(1), 3924. https://doi.org/10.1038/s41467-020-17834-w Cite
Calidi Biotherapeutics, Inc., announced that the Investigational New Drug application submitted by its partner, Personalized Stem Cells, Inc. They have received FDA approval for the treatment of COVID-19 and pneumonia patients using stem cell therapy.
[Calidi Biotherapeutics, Inc.]
Scientists describe our current knowledge of the complex interplay between SARS-CoV-2 infection and the IFN system, highlighting some of the gaps that need to be filled for a better understanding of the underlying molecular mechanisms.
With multiple COVID-19 vaccines in and approaching Phase III trials, the FDA has released development and licensure guidelines for these products. The 21-page guidelines detail agency recommendations on everything from manufacturing and preclinical data considerations to trial design, efficacy considerations and post-licensure safety.
[Nature Reviews Drug Discovery]
To investigate the safety of Bacille Calmette-Guérin (BCG) vaccination, scientists retrospectively assessed COVID-19 and related symptoms in three cohorts of healthy volunteers who either received BCG in the last five years or not.
[Cell Reports Medicine]
6445212 TEH8CY66 items 1 apa default asc 1
Moorlag, S. J. C. F. M., Deuren, R. C. van, Werkhoven, C. H. van, Jaeger, M., Debisarun, P., Taks, E., Mourits, V. P., Koeken, V. A. C. M., Bree, L. C. J. de, Doesschate, T. ten, Cleophas, M. C., Smeekens, S., Oosting, M., Veerdonk, F. L. van de, Joosten, L. A. B., Oever, J. ten, Meer, J. W. M. van der, Curtis, N., Aaby, P., … Netea, M. G. (2020). Safety and COVID-19 symptoms in individuals recently vaccinated with BCG: a retrospective cohort study. Cell Reports Medicine, 0(0). https://doi.org/10.1016/j.xcrm.2020.100073 Cite
Scientists report on a systems-level blood immunomonitoring study of 37 adult patients diagnosed with COVID-19 and followed with up to 14 blood samples from acute to recovery phases of the disease.
[Cell Reports Medicine]
6445212 H2RWB95V items 1 apa default asc 1
Rodriguez, L., Pekkarinen, P. T., Lakshmikanth, T., Tan, Z., Consiglio, C. R., Pou, C., Chen, Y., Mugabo, C. H., Nguyen, N. A., Nowlan, K., Strandin, T., Levanov, L., Mikes, J., Wang, J., Kantele, A., Hepojoki, J., Vapalahti, O., Heinonen, S., Kekäläinen, E., & Brodin, P. (2020). Systems-level immunomonitoring from acute to recovery phase of severe COVID-19. Cell Reports Medicine, 0(0). https://doi.org/10.1016/j.xcrm.2020.100078 Cite
Using human blood samples derived before the SARS-CoV-2 virus was discovered in 2019, the authors mapped 142 T cell epitopes across the SARS-CoV-2 genome to facilitate precise interrogation of the SARS-CoV-2-specific CD4+ T cell repertoire.
6445212 WTK6GDNY items 1 apa default asc 1
Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S. I., Dan, J. M., Burger, Z. C., Rawlings, S. A., Smith, D. M., Phillips, E., Mallal, S., Lammers, M., Rubiro, P., Quiambao, L., Sutherland, A., Yu, E. D., Antunes, R. da S., Greenbaum, J., Frazier, A., … Weiskopf, D. (2020). Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. https://doi.org/10.1126/science.abd3871 Cite
Pfizer, Inc. and BioNTech SE announced an agreement with the Ministry of Health, Labour and Welfarein Japan to supply 120 million doses of BNT162 mRNA-based vaccine candidate against SARS-CoV-2, subject to clinical success and regulatory approval, beginning in 2021.
[Pfizer, Inc. ]
Researchers examined 19 COVID-19 exposed placentas for histopathologic findings, and for expression of ACE2, and TMPRSS2 by immunohistochemistry.
6445212 F8UD6PVM items 1 apa default asc 1
Hecht, J. L., Quade, B., Deshpande, V., Mino-Kenudson, M., Ting, D. T., Desai, N., Dygulska, B., Heyman, T., Salafia, C., Shen, D., Bates, S. V., & Roberts, D. J. (2020). SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers. Modern Pathology, 1–12. https://doi.org/10.1038/s41379-020-0639-4 Cite